Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has been given a consensus recommendation of “Hold” by the twelve ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.57.

TTPH has been the topic of several research reports. ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Thursday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Friday, August 3rd. HC Wainwright boosted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 28th. Finally, B. Riley boosted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 28th.

Shares of Tetraphase Pharmaceuticals stock traded up $0.11 on Wednesday, hitting $1.90. The stock had a trading volume of 277,100 shares, compared to its average volume of 992,429. Tetraphase Pharmaceuticals has a twelve month low of $1.75 and a twelve month high of $6.96. The company has a market capitalization of $98.67 million, a price-to-earnings ratio of -0.72 and a beta of 2.67.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Tetraphase Pharmaceuticals had a negative net margin of 432.40% and a negative return on equity of 65.89%. The firm had revenue of $1.15 million during the quarter, compared to analyst estimates of $2.09 million. Sell-side analysts predict that Tetraphase Pharmaceuticals will post -1.41 EPS for the current year.

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of Tetraphase Pharmaceuticals by 3.4% in the third quarter. BlackRock Inc. now owns 4,316,258 shares of the biopharmaceutical company’s stock valued at $11,914,000 after buying an additional 143,944 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Tetraphase Pharmaceuticals by 14.4% in the third quarter. Dimensional Fund Advisors LP now owns 2,517,623 shares of the biopharmaceutical company’s stock valued at $6,949,000 after buying an additional 317,210 shares during the period. Northern Trust Corp boosted its stake in shares of Tetraphase Pharmaceuticals by 3.5% in the second quarter. Northern Trust Corp now owns 1,060,816 shares of the biopharmaceutical company’s stock valued at $3,787,000 after buying an additional 36,115 shares during the period. Man Group plc boosted its stake in shares of Tetraphase Pharmaceuticals by 19.9% in the third quarter. Man Group plc now owns 884,415 shares of the biopharmaceutical company’s stock valued at $2,441,000 after buying an additional 146,700 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 40.0% in the third quarter. Renaissance Technologies LLC now owns 873,227 shares of the biopharmaceutical company’s stock valued at $2,410,000 after buying an additional 249,342 shares during the period. Institutional investors and hedge funds own 40.68% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.